Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 238

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

Wheler, Jennifer J., Janku, Filip, Naing, Aung, Li, Yali, Stephen, Bettzy, Zinner, Ralph, Subbiah, Vivek, Fu, Siqing, Karp, Daniel, Falchook, Gerald S., Tsimberidou, Apostolia M., Piha-Paul, Sarina, Anderson, Roosevelt, Ke, Danxia, Miller, Vincent, Yelensky, Roman, Lee, J. Jack, Hong, David S., Kurzrock, Razelle·2016·Cancer Research

Abstract

Innovative molecular diagnostics deployed in the clinic enable new ways to stratify patients into appropriate treatment regimens. These approaches may resolve a major challenge for early-phase clinical trials, which is to recruit patients who, while having failed previous treatments, may nevertheless respond to molecularly targeted drugs. We report the findings of a prospective, single-center study conducted in patients with diverse refractory cancers who underwent comprehensive genomic profiling (CGP; next-generation sequencing, 236 genes). Of the 500 patients enrolled, 188 (37.6%) received either matched (N = 122/188, 65%) or unmatched therapy (N = 66/188, 35%). The most common reasons that patients were not evaluable for treatment included insufficient tissue, death, or hospice transfer. The median number of molecular alterations per patient was five (range, 1–14); median number of prior therapies, four. The most common diagnoses were ovarian cancer (18%), breast cancer (16%), sarcoma (13%), and renal cancer (7%). Of the 339 successfully profiled patients, 317 (93.5%) had at least one potentially actionable alteration. By calculating matching scores, based on the number of drug matches and genomic aberrations per patient, we found that high scores were independently associated with a greater frequency of stable disease ≥6 months/partial/complete remission [22% (high scores) vs. 9% (low scores), P = 0.024], longer time-to-treatment failure [hazard ratio (HR) = 0.52; 95% confidence interval (CI) = 0.36–0.74; P = 0.0003], and survival (HR = 0.65; 95% CI = 0.43–1.0; P = 0.05). Collectively, this study offers a clinical proof of concept for the utility of CGP in assigning therapy to patients with refractory malignancies, especially in those patients with multiple genomic aberrations for whom combination therapies could be implemented. Cancer Res; 76(13); 3690–701. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-15-3043

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 238

Metadata

Authors
Wheler, J. J., Janku, F., Naing, A., Li, Y., Stephen, B., Zinner, R., Subbiah, V., Fu, S., Karp, D., Falchook, G. S., Tsimberidou, A. M., Piha-Paul, S., Anderson, R., Ke, D., Miller, V., Yelensky, R., Lee, J. J., Hong, D. S., & Kurzrock, R.
Venue
Cancer Research
Published
2016-06-30
Volume
76
Issue
13
Pages
3690-3701
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2408112818
Cited by
238
References
4
FWCI
12.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. https://app.cochat.ai/papers/10.1158/0008-5472.can-15-3043
The paper
Wheler, J. J., Janku, F., Naing, A., Li, Y., Stephen, B., Zinner, R., Subbiah, V., Fu, S., Karp, D., Falchook, G. S., Tsimberidou, A. M., Piha-Paul, S., Anderson, R., Ke, D., Miller, V., Yelensky, R., Lee, J. J., Hong, D. S., & Kurzrock, R. (2016). Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Research. https://doi.org/10.1158/0008-5472.can-15-3043

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.